Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 3

V+PSF-M for Tobacco Cessation in HIV Care in India

NCT05786547 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this research study is to test an intervention to help quit tobacco use in participants with Human Immunodeficiency Virus (HIV). The study interventions used in this research study are: * Positively Smoke Free - Mobile (PSF-M) (mobile behavioral program) * Varenicline (or Chantix, apovarenicline, Champix or Nocrav)

Interventions

  • DRUG Varenicline
  • BEHAVIORAL Standard Care
  • BEHAVIORAL Positively Smoke Free Mobile (PSF-M)

Study Locations (2)

Colorado

  • University of Colorado — Aurora

Tamil Nadu

  • VHS Infectious Disease Medical Centre, CART Clinical Research Site — Chennai

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2024-01-02
Est. Completion 2026-07-22
Phase Phase 3

Sponsor

University of Colorado, Denver

1,447 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05786547

The ClinicalTrials.gov registry entry for NCT05786547 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,447 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 3 interventions — of which Varenicline is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05786547 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Colorado, Tamil Nadu. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05786547 about?

NCT05786547 is a clinical study titled "V+PSF-M for Tobacco Cessation in HIV Care in India". The goal of this research study is to test an intervention to help quit tobacco use in participants with Human Immunodeficiency Virus (HIV). The study interventions used in this research study are: * Positively Smoke Free - Mobile (PSF-M) (mobile behavioral program) * Varenicline (or Chantix, apov...

What is the current status of trial NCT05786547?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2024-01-02. Estimated completion is 2026-07-22.

What conditions does trial NCT05786547 study?

This clinical trial studies the following conditions: Smoking Cessation, Human Immunodeficiency Virus, Smoking, Tobacco. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05786547?

The interventions under investigation include: Varenicline (DRUG), Standard Care (BEHAVIORAL), Positively Smoke Free Mobile (PSF-M) (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05786547?

This trial is sponsored by University of Colorado, Denver, which has 1,447 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05786547 being conducted?

This trial has 2 study locations across Colorado, Tamil Nadu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial